 |
|
gefitinib
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| US brand name: | | Iressa | | | | Code name: | | ZD 1839 | | | | Chemical structure names: | | - 4-(3Chloro-4-flurophenylamine)-7-methoxy-6(3-(4morpholinyl)quinazoline
- 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-morpholin] propoxy]
| | |
|
|
